ALS drug trial halted: what happened with BIIB105?

NCT ID NCT04494256

Terminated Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called BIIB105 in adults with ALS, a progressive nerve disease. The trial had two parts: a 6-month placebo-controlled phase and a 3-year open-label extension where everyone received the drug. The goal was to check safety, how the body processes the drug, and whether it could slow disease progression. However, the study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BIIB105
What this could lead to: If it works, this could point toward a treatment that slows the worsening of ALS symptoms.
What could go wrong: This early-stage trial was terminated, so results are limited. The drug is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

A.O.U. Città della salute e della scienza di Torino

Torino, Italy
ALS Clinic - Department of Neurology, Neuromuscular Division, Johns Hopkins University, School of Medicine

Baltimore, Maryland, 21218, United States
Barrow Neurological Institute

Phoenix, Arizona, 85013, United States
Georgetown University

Washington D.C., District of Columbia, 20007-2113, United States
Houston Methodist Neurological Institute

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Montreal Neurological Institute-Hospital

Montreal, Quebec, H3A 2B4, Canada
Orlando Health

Orlando, Florida, 32806, United States
Stanford Neuromuscular Research Center

Palo Alto, California, 94305, United States
The Emory Clinic

Atlanta, Georgia, 30322, United States
UMC Utrecht

Utrecht, 3584 CX, Netherlands
University of California San Diego Medical Center

La Jolla, California, 92037, United States
University of Colorado Hospital - Neuroscience Center -Anschutz Medical Campus

Aurora, Colorado, 80045, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Utah

Salt Lake City, Utah, 84132, United States
Washington University, School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.